201 related articles for article (PubMed ID: 29131017)
1. Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry.
Bacha F; Cheng P; Gal RL; Kollman C; Tamborlane WV; Klingensmith GJ; Manseau K; Wood J; Beck RW;
Horm Res Paediatr; 2018; 89(1):47-55. PubMed ID: 29131017
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control in youth-onset type 2 diabetes correlates with weight loss.
Chang N; Yeh MY; Raymond JK; Geffner ME; Ryoo JH; Chao LC
Pediatr Diabetes; 2020 Nov; 21(7):1116-1125. PubMed ID: 33103329
[TBL] [Abstract][Full Text] [Related]
3. HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes.
Zeitler P; Hirst K; Copeland KC; El Ghormli L; Levitt Katz L; Levitsky LL; Linder B; McGuigan P; White NH; Wilfley D;
Diabetes Care; 2015 Dec; 38(12):2285-92. PubMed ID: 26537182
[TBL] [Abstract][Full Text] [Related]
4. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study.
Wolf RM; Cheng P; Gal RL; Beaulieu LC; Kollman C; Isganaitis E; Magge S; Mastrandrea LD; Klingensmith GJ; Tamborlane W; Van Name M;
Pediatr Diabetes; 2022 Jun; 23(4):439-446. PubMed ID: 35138021
[TBL] [Abstract][Full Text] [Related]
5. Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
Agbaje OF; Coleman RL; Hattersley AT; Jones AG; Pearson ER; Shields BM; Holman RR;
Diabetes Res Clin Pract; 2020 Aug; 166():108333. PubMed ID: 32702468
[TBL] [Abstract][Full Text] [Related]
6. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Libman IM; Miller KM; DiMeglio LA; Bethin KE; Katz ML; Shah A; Simmons JH; Haller MJ; Raman S; Tamborlane WV; Coffey JK; Saenz AM; Beck RW; Nadeau KJ;
JAMA; 2015 Dec; 314(21):2241-50. PubMed ID: 26624824
[TBL] [Abstract][Full Text] [Related]
7. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
[TBL] [Abstract][Full Text] [Related]
8. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
9. Time to failure of oral therapy in children with type 2 diabetes: a single center retrospective chart review.
Barnes NS; White PC; Hutchison MR
Pediatr Diabetes; 2012 Nov; 13(7):578-82. PubMed ID: 22646303
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the USA: enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry.
Nambam B; Silverstein J; Cheng P; Ruedy KJ; Beck RW; Paul Wadwa R; Klingensmith G; Willi SM; Wood JR; Bacha F; Thomas IH; Tamborlane WV;
Pediatr Diabetes; 2017 May; 18(3):222-229. PubMed ID: 26970319
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
14. Glycemic excursions are positively associated with HbA1c reduction from baseline after treatment with acarbose in patients with type 2 diabetes on metformin monotherapy.
Wang JS; Lee IT; Lee WJ; Lin SD; Su SL; Tu ST; Tseng YH; Lin SY; Sheu WH
J Diabetes; 2017 Mar; 9(3):248-255. PubMed ID: 27043224
[TBL] [Abstract][Full Text] [Related]
15. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium.
Klingensmith GJ; Connor CG; Ruedy KJ; Beck RW; Kollman C; Haro H; Wood JR; Lee JM; Willi SM; Cengiz E; Tamborlane WV;
Pediatr Diabetes; 2016 Jun; 17(4):266-73. PubMed ID: 25951940
[TBL] [Abstract][Full Text] [Related]
16. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
[TBL] [Abstract][Full Text] [Related]
17. Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry database.
Aronson R; Orzech N; Ye C; Goldenberg R; Brown V
J Diabetes; 2016 Jan; 8(1):76-85. PubMed ID: 25565383
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Frias JP; Zimmer Z; Lam RLH; Amorin G; Ntabadde C; Iredale C; O'Neill EA; Engel SS; Kaufman KD; Makimura H; Crutchlow MF
Diabetes Obes Metab; 2019 May; 21(5):1128-1135. PubMed ID: 30609212
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Frías JP; Hardy E; Ahmed A; Öhman P; Jabbour S; Wang H; Guja C
Diabetes Obes Metab; 2018 Jun; 20(6):1520-1525. PubMed ID: 29573139
[TBL] [Abstract][Full Text] [Related]
20. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
